Supporting families of children with high-risk neuroblastoma
Part of Cancer clinical trials.
This study tests a resource intervention to help families with low income who have a child with high-risk neuroblastoma. It aims to reduce financial stress and improve care during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been newly diagnosed with high-risk neuroblastoma and started cancer therapy at a study hospital.
- Your family has a low income (less than 200% of the federal poverty level).
- Your child is between 0 and 17 years old.
- Your family lives in one of these states: MA, PA, IL, CA, WA, CT, GA, WI, or OH.
- Your child has not yet started the third round of induction chemotherapy.
- Your child may be on the ANBL2131 study or receiving standard cancer care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.